CYTOGENETIC STUDIES IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA FOLLOWING A MYELODYSPLASTIC SYNDROME

被引:3
作者
WEH, HJ
KUSE, R
SEEGER, D
SUCIU, S
HOSSFELD, DK
机构
[1] Department of Oncology and Hematology, Medical University Clinic, Hamburg
[2] Department of Hematology, AK St. Georg, Hamburg
关键词
CYTOGENETIC STUDIES; AML; LEUKEMIA; MYELODYSPLASIA; MDS;
D O I
10.3109/10428199109070287
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between 1981 and 1988, thirty-nine patients with acute myeloid leukemia (AML) following a de novo myelodysplastic syndrome (n-MDS) were studied cytogenetically. The chromosomal aberration rate was 59%. The anomalies most often found were: complex (four or more) aberrations (n = 6), a 5q- chromosome (n = 6), monosomy 7 or a 7q- chromosome and trisomy 8 as the sole defect (n = 3). Incidence and types of chromosomal aberrations were approximately the same as in myelodysplastic syndromes and in 191 patients with de novo AML studied in our laboratory during the same period. But the cytogenetic pattern in AML post de novo MDS also shared certain similarities with chromosomal findings in 35 patients with secondary, therapy-induced (t) AML/MDS. In both these types of acute leukemia primary changes such as t(8;21), t(15;17) and inv (16) were not found; the frequency of AA-Karyotypes was high (70 and 66%) and the incidence of -5,5q- in AML post de novo MDS was more comparable with that found in t-AML/MDS than in de novo AML. Thus the chromosomal patterns seen in AML post de novo MDS indicate that these leukemias share similarities with both de novo and t-AML not only clinically but also cytogenetically. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:423 / 427
页数:5
相关论文
共 25 条
[1]  
Koeffer H.P., Golde D.W., Human Preleukemia, Annals of Internal Medicine, 93, pp. 347-353, (1980)
[2]  
Rosenthal D.S., Moloney W.C., Refractory, dysmyelopoietic anemia and acute leukemia, Blood, 63, pp. 314-318, (1984)
[3]  
Tricot G., Mecucci C., van den Berghe H., Evolution of the myelodysplastic syndromes, British Journal of Haematology, 63, pp. 609-614, (1986)
[4]  
Kantarjian H.M., Keating M.J., Therapy-related leukemia and myelodysoplastic syndrome, Seminars in Oncology, 14, pp. 435-443, (1987)
[5]  
Overview of association between chromosome pattern and cell morphology, age, sex and race, Cancer Genetics and Cytogenetics, 11, pp. 265-274, (1984)
[6]  
Morphologic, immunologic, and cytogenetic (MIC) working classification ofthe acute myeloid leukemias, Cancer Genetics and Cytogenetics, 30, pp. 1-15, (1988)
[7]  
Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: a cooperative study, Cancer Genetics and Cytogenetics, 12, pp. 95-104, (1984)
[8]  
Le Beau M.M., Albain K.S., Larson R.A., Vardiman J.W., Davis E.M., Blough R.R., Golomb H.M., Rowley J.D., Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute non-lymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no 5 and 7, Journal of Clinical Oncology, 4, pp. 325-345, (1986)
[9]  
Pedersen-Bjergaard J., Philip P., Cytogenetic characteristics of therapy-related acute nonlymphocytic leukemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases, British Journal of Haematology, 66, pp. 199-207, (1987)
[10]  
Whang-Peng J., Young R.C., Lee E.C., Longo D.L., Schechter G.P., De Vita V.T., Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities, Blood, 71, pp. 403-414, (1988)